Proactive Investors - Run By Investors For Investors

Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019

Tim Higenbottam, R&D director at hay fever vaccine specialist Allergy Therapeutics (LON:AGY) tells Proactive Investors GrassMATAMPL is one of its two most advanced products in development.
He hopes the company will be in a position to start phase III studies at some point this year.
The company aims to launch the ground-breaking and "exciting" grass pollen allergy treatment in 2019 after all the trials are completed and the treatment is approved.

Meet Jersey Oil and Gas PLC, Chariot Oil and Gas, OPG Power Ventures Plc. and European Metals Holdings Ltd at our event, London, 09 March 2017. Register here »
View full AGY profile

Allergy Therapeutics plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.